Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3CNS 2Breast 2Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Glioblastoma 94Glioma 32Brain Neoplasms 29Melanoma 21Neoplasms 17Astrocytoma 17Sarcoma, Ewing 7Ovarian Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 6Neoplasm Metastasis 6Medulloblastoma 6Breast Neoplasms 6Sarcoma 5Recurrence 5Diffuse Intrinsic Pontine Glioma 5Small Cell Lung Carcinoma 4Rhabdomyosarcoma 4Oligodendroglioma 4Spinal Cord Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Central Nervous System Neoplasms 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Neuroendocrine Tumors 2Lymphoma, Follicular 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Temozolomide × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Sapience Therapeutics

Phase 1/2 Active not recruiting
125 enrolled
BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT01085422 2017-11-21

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

AbbVie

Phase 1 Completed
35 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡